undamentalytics Newsletter
Sign in

Abcellera Biologics Inc. balance sheet

At the end of fiscal 2025, Abcellera Biologics Inc. had total assets of $1.36bn, total liabilities of $390m and shareholders' equity of $967m. It held $129m in cash against $0 of debt: net cash of $129m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents—594476387133156129120
Receivables—1——0323938
Inventory—————068
Total current assets—8139301,025872751728679
Goodwill—32484848484848
Total assets—1,0061,3191,5411,4881,3611,3571,308
Deferred revenue (current)—782219141421
Total current liabilities—103121118119776453
Short-term debt—0——————
Total debt—0000000
Total liabilities—175293308336304390412
Shareholders' equity108311,0261,2331,1521,056967896
Net debt (negative = net cash)—−594−476−387−133−156−129−120
Shares outstanding—269m283m287m291m296m301m306m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ABCL vs CYTKABCL vs CUVLABCL vs RXRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Abcellera Biologics Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Abcellera Biologics Inc.